Man Chen

发表

Proof of principle for epitope-focused vaccine design

David Baker, Eric Stevens, Man Chen, 2014, Nature.

Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus.

W. Schief, B. Correia, P. Kwong, 2011, Journal of molecular biology.

Structural basis of respiratory syncytial virus neutralization by motavizumab

P. Kwong, B. Graham, Man Chen, 2010, Nature Structural &Molecular Biology.

Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

Cinque S. Soto, U. Baxa, G. Chuang, 2013, Science.

Corrigendum: Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state

Barney S. Graham, Daniel Wrapp, Jason S. McLellan, 2017, Nature Communications.

Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera

G. Chuang, M. Sastry, I. Georgiev, 2015, Science Translational Medicine.

Epitope-Specific Regulatory CD4 T Cells Reduce Virus-Induced Illness while Preserving CD8 T-Cell Effector Function at the Site of Infection

B. Graham, Man Chen, T. R. Johnson, 2010, Journal of Virology.

Respiratory Syncytial Virus (RSV) Neutralizing Antibodies at Birth Predict Protection from RSV Illness in Infants in the First 3 Months of Life

M. Levine, B. Graham, Man Chen, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen

S. Reddy, P. Gainza, B. Correia, 2018, bioRxiv.

Broadly neutralizing antibodies target the coronavirus fusion peptide

Peter D. Crompton, J. Mascola, J. Yewdell, 2022, bioRxiv.

Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial.

J. Mascola, R. Bailer, B. Graham, 2021, The Lancet. Respiratory medicine.

A proof of concept for structure-based vaccine design targeting RSV in humans

J. Mascola, P. Kwong, B. Graham, 2019, Science.

Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state

M. Kanekiyo, B. Graham, Man Chen, 2017, Nature Communications.

Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector

P. Kwong, B. Graham, Syed M. Moin, 2016, Journal of Virology.

Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant.

J. Mascola, M. Sastry, I. Georgiev, 2016, Bioconjugate chemistry.

Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody

U. Baxa, T. Zhou, P. Kwong, 2013, Science.

A multispecific antibody confers pan-reactive SARS-CoV-2 neutralization and prevents immune escape

J. Mascola, R. Koup, N. Sullivan, 2022, bioRxiv : the preprint server for biology.

Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability

J. Mascola, M. Sastry, Reda Rawi, 2022, Structure.

Broadly neutralizing antibodies target the coronavirus fusion peptide

Peter D. Crompton, J. Mascola, J. Yewdell, 2022, Science.

Divergent age-related humoral correlates of protection against respiratory syncytial virus infection in older and young adults: a pilot, controlled, human infection challenge model.

B. Graham, Man Chen, R. Thwaites, 2022, The Lancet. Healthy longevity.

EpitopeImmunopathology Caused by a Dominant Cell Epitope Protect against T + Responses against a Subdominant CD8

B. Graham, Man Chen, Jie Liu, 2010 .

Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses

Peter D. Crompton, J. Mascola, J. Yewdell, 2022, Cell Host & Microbe.

Iterative structure-based improvement of a respiratory syncytial virus fusion glycoprotein vaccine

Cinque S. Soto, U. Baxa, J. Mascola, 2016 .

A multispecific antibody prevents immune escape and confers pan-SARS-CoV-2 neutralization

J. Mascola, Juan Li, R. Koup, 2022, bioRxiv.

Modified Vaccinia Virus Ankara Immunization Protects against Lethal Challenge with Recombinant Vaccinia Virus Expressing Murine Interleukin-4

B. Graham, Man Chen, T. R. Johnson, 2004, Journal of Virology.

Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones

Chaim A. Schramm, Alexander M Schrager, J. Mascola, 2022, bioRxiv.

Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability

J. Mascola, M. Sastry, Reda Rawi, 2022, bioRxiv.

Vaccination with Human Papillomavirus Pseudovirus-Encapsidated Plasmids Targeted to Skin Using Microneedles

M. Prausnitz, B. Graham, Man Chen, 2015, PloS one.

Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors

B. Graham, Syed M. Moin, L. Walker, 2016, Science Immunology.

Epitope-Specific Serological Assays for RSV: Conformation Matters

M. Kanekiyo, B. Graham, Man Chen, 2019, Vaccines.

Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation

A. Sivasubramanian, B. Graham, Syed M. Moin, 2018, Immunity.

Convergent epitope specificities, V gene usage and public clones elicited by primary exposure to SARS-CoV-2 variants.

Chaim A. Schramm, Alexander M Schrager, J. Mascola, 2022, bioRxiv : the preprint server for biology.

Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus

J. Mascola, G. Chuang, M. Sastry, 2017, PloS one.

Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus

J. Mascola, M. Sastry, I. Georgiev, 2016, PloS one.

Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate

P. Kwong, B. Graham, Syed M. Moin, 2017, Journal of Virology.

TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity.

B. Graham, Man Chen, Srinivas S. Rao, 2009, Vaccine.

T Cell Receptor Clonotype Influences Epitope Hierarchy in the CD8+ T Cell Response to Respiratory Syncytial Virus Infection*

P. Dash, P. Thomas, B. Graham, 2010, The Journal of Biological Chemistry.

Characterization of Respiratory Syncytial Virus M- and M2-Specific CD4 T Cells in a Murine Model

B. Graham, Man Chen, T. R. Johnson, 2009, Journal of Virology.

Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability

J. Mascola, M. Sastry, Reda Rawi, 2022, Structure.

Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529

J. Mascola, N. Sullivan, Baoshan Zhang, 2021, bioRxiv.

Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B

J. Mascola, G. Chuang, I. Georgiev, 2019, Pathogens & immunity.

Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein

M. Kanekiyo, B. Graham, Syed M. Moin, 2017, Nature Communications.

Iterative structure-based improvement of a respiratory syncytial virus fusion glycoprotein vaccine

Cinque S. Soto, U. Baxa, J. Mascola, 2016, Nature Structural &Molecular Biology.

A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus

Cinque S. Soto, U. Baxa, J. Mascola, 2015, PloS one.

Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein

U. Baxa, B. Graham, Syed M. Moin, 2015, PLoS pathogens.

Mucosal Delivery of Human Papillomavirus Pseudovirus-Encapsidated Plasmids Improves Potency of DNA Vaccination

B. Graham, Man Chen, J. Schiller, 2010, Mucosal Immunology.

Responses against a Subdominant CD8+ T Cell Epitope Protect against Immunopathology Caused by a Dominant Epitope

B. Graham, Man Chen, P. Collins, 2010, The Journal of Immunology.

Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater In Vivo Protection than the Murine Precursor of Palivizumab

B. Graham, Man Chen, J. McLellan, 2017, Journal of Virology.

Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability

J. Mascola, M. Sastry, Reda Rawi, 2022, Structure.

Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity

Gregory D. Gromowski, Hongjun Bai, R. Koup, 2023, Journal of virology.

Structure of a Major Antigenic Site on the Respiratory Syncytial Virus Fusion Glycoprotein in Complex with Neutralizing Antibody 101F

P. Kwong, B. Graham, Man Chen, 2010, Journal of Virology.

Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery

J. Mascola, R. Koup, Baoshan Zhang, 2023, NPJ vaccines.

A Conserved Mechanism for Centromeric Nucleosome Recognition by Centromere Protein CENP-C

U. Baxa, A. Straight, R. Ghirlando, 2013, Science.

Enhancing Anti-SARS-CoV-2 Neutralizing Immunity by Genetic Delivery of Enveloped Virus-like Particles Displaying SARS-CoV-2 Spikes

J. Mascola, R. Koup, Reda Rawi, 2023, Vaccines.